Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd. has received approval from an Independent Safety Committee to administer a higher 4,000mg dose of its anti-infective drug R327 intravenously in a rapid 30-minute infusion for a Phase I/II clinical trial targeting Urinary Tract Infection/Urosepsis. Following successful tests at lower doses, this escalation marks a significant step in evaluating the drug’s efficacy against antibiotic-resistant infections. The ongoing trial is set to commence dosing with the increased amount on recruited participants shortly.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
